Dr. Hiroshi Maeda

Title: The EPR-Effect is the Key in Cancer Treatment Beyond Chemotherapy: Augmentation of EPR-Effect and Innovation in Photodynamic Therapy (PDT) and Boron-Neutron Therapy (BNCT)


Hiroshi Maeda is the Director, BioDynamics Research Foundation and Professor Emeritus Kumamoto University (Med), Senior Invited Professor of Osaka University Medical School, Director, Special Appointee Professor of Tohoku University.

He is a world-renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku UniversityHe published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 120.

No Content found...